Tag: David Hoey
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).Â
Vaxxas’ new needle-free vaccine manufacturing plant opens in Queensland
Biotechnology company Vaxxas has completed work on its new needle-free vaccine technology manufacturing facility in Northshore Hamilton.Â
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.Â
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
